Somebody shaking the tree. Down 12 % during the last hour.
Closed at near low of day but volume remains fairly low @77,299 shares as compared with daily average 91,704 shares. No post-market trading so far. Prana rumors usually go the other way - temporarily up instead of this dip.
Beware those who ignore statistics but claim superiority with nothing to sell PRAN........$20.8M market capitalization LLY............$87.415B PFE...........197.83B JNJ............335.181B MRK..........176.35B
Anyone familiar with this research? Binghampton Univ. just announced a Parkinson's drug:
New drug may treat and limit progression of Parkinson's disease
Researchers at Binghamton University have developed a new drug that may limit the progression of Parkinson's disease while providing better symptom relief to potentially hundreds of thousands of people with the disease.
Scott Ayton, Amir Fazlollahi, Pierrick Bourgeat, Parnesh Raniga, Amanda Ng ... Published: 26 July 2017 Abstract See Derry and Kent (doi:10.1093/awx167) for a scientific commentary on this article. The large variance in cognitive deterioration in subjects who test positive for amyloid-β by positron emission tomography indicates that convergent pathologies, such as iron accumulation, might combine with amyloid-β to accelerate Alzheimer’s disease progression. Here, we applied quantitative susceptibility mapping, a relatively new magnetic resonance imaging method sensitive to tissue iron, to assess the relationship between iron, amyloid-β load, and cognitive decline in 117 subjects who underwent baseline magnetic resonance imaging and amyloid-β positron emission tomography from the Australian Imaging, Biomarkers and Lifestyle study (AIBL). Cognitive function data were collected every 18 months for up to 6 years from 100 volunteers who were either cognitively normal (n = 64) or diagnosed with mild cognitive impairment (n = 17) or Alzheimer’s disease (n = 19). Among participants with amyloid pathology (n = 45), higher hippocampal quantitative susceptibility mapping levels predicted accelerated deterioration in composite cognition tests for episodic memory [β(standard error) = −0.169 (0.034), P = 9.2 × 10−7], executive function [β(standard error) = −0.139 (0.048), P = 0.004), and attention [β(standard error) = −0.074 (0.029), P = 0.012]. Deteriorating performance in a composite of language tests was predicted by higher quantitative susceptibility mapping levels in temporal lobe [β(standard error) = −0.104 (0.05), P = 0.036] and frontal lobe [β(standard error) = −0.154 (0.055), P = 0.006]. These findings indicate that brain iron might combine with amyloid-β to accelerate clinical progression and that quantitative susceptibility mapping could be used in combination with amyloid-β positron emission tomography to stratify individuals at risk of decline.
MicroCap Alert to PRAN shareholders. Why Clean Energy Technologies (CETY) shares moved up recently and why they are about to rise sharply again. CETY purchased their Heat Recovery Systems from General Electric. Each system sells for about $300,000. Demand for CETY HRS is very strong. CETY just expanded Europe sales and service office in high demand market CETY immediately announced first new sale in Europe CETY presenting to 26 Power Companies in the Pacific on July 31st to August 4th – These 26 power companies need CETY HRS to produce power cheaper and make more profits.
Expect substantial sales orders to flow soon after conference CETY 1017 target: $.15 to $.20
This is more like it. Takeda, market cap $40billion, now on board with PBT434 development. Been waiting for a Pharma to recognize the potential of Prana's MPACs for some time. From one year ago: [NEW YORK (TheStreet) -- Takeda Pharmaceutical (TKPYY) is looking for potential multi-billion dollar deals in the U.S. and other overseas markets as the Japanese pharmaceutical giant seeks to lower its dependence on sluggish domestic sales.
Takeda CEO Christophe Weber would not confirm earlier reports that the company had set aside $10 billion to $15 billion for acquisitions, according to Reuters. Weber said the company is exploring more deals as Takeda has refocused several initiatives and is overhauling its research activities.] Looks like they just spotted the bargain of the decade. IMO
Is PRAN selling at cash value? That's quite amazing given her potentials.
If we are to go off the RSI then you could argue that a pull back next day or so could occur on PRAN before rallying up. if you guys have questions you should ask awe*some*stock*s. They often respond to my emails which is helpful.
KTOV = Mcap $16 Mil /Cash $17 Mil / ULTRA Low float O/S 10.6 M / NDA submission for potential Blockbuster this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys
Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.
KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously
Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial
Marketing potential Pipeline candidates address large, multi-billion dollar markets
“KIT-302 has the potential to address the multi-billion dollar market for the treatment of osteoarthritis pain and hypertension with one drug that reduces patients’ risk of suffering a heart attack or stroke, while also reducing cost for payers. There is currently no single medication on the market that treats both osteoarthritis pain and hypertension and thus, KIT-302 will be the only NSAID indicated both to treat pain and to reduce the risk of heart attack, stroke and death.”
Pain medications for osteoarthritis account for billions of dollars in annual sales globally. Most pain medications for osteoarthritis, including celecoxib which had global sales of $2.7 billion in 2014, are non-steroidal anti-inflammatory drugs (NSAIDs) which have the side effect of elevating blood pressure, and increasing the risk of heart attacks, strokes and death. Of the 27 million Americans who live with osteoarthritis, 13.5 million also suffer from hypertension, which also increases the risk of heart attack, stroke, and death.
ASX announcement today: Takeda Japan and Prana PD preclinical PBT434 investigative collaboration. Appears that they will study Parkinson's gastro-intestinal neuropathology and continue plan for Phase I later this year. No description of part each company will play in the collaboration which was reported by Prana, no input yet from Takeda.
Release Date: 18/07/17 10:04 Summary: Prana commences research collaboration with Takeda Price Sensitive: Yes Download Document 618.4KB.
The scenarios are quite interesting at current levels for PRAN. I started receiving notifications from awe-SOME-stock-s the other week and so far they have presented interesting new trade ideas.
It's questionable if anyone is alive and well at Prana headquarters. A vague "price sensitive" announcement about an investigative collaborative research deal with Takeda, a Japanese international corporation, contained few details. A few posters were ecstatic but there was no actual follow-up, especially no input from Takeda about what they could do for PBT434 in preclinical stage.
Does anyone wonder why Frances (aka Copper, xrx2 on hotcopper who got banned) keeps stalking PRAN and PBT? Textbook definition of a STALKER. Get a life you Loser!
Prana seems to be comfortable remaining in the $2.70's range.....bid $2.73 x 100, ask $2.77 x 1,900. PBT appears to be content with a nickel to six cents range. Volume stays low as per usual daily.